KPV

Nanomolar in a Dish Is Not a Dose

UKPWritten and published by UK Peptides4 min readUpdated 3 cited sources

The short answer

The KPV literature rests on three immortalised human cell lines and two chemically induced mouse colitis models. Each is a legitimate research tool with a specific and limited scope, and the distance between a nanomolar effect in a reporter assay and anything clinical is very large.

Key facts

Epithelial lines used
Caco2-BBE, HT29-Cl.19A
Immune line used
Jurkat, a human T-cell line
What Caco-2 derives from
Human colon adenocarcinoma
Mouse colitis models used
DSS and TNBS
Tumorigenesis model used
AOM/DSS
Typical readout
NF-kappaB luciferase reporter, cytokine mRNA and protein
Reported in vitro active range
Nanomolar
Registered human trials of KPV
None

Why this article exists in a category about a molecule

Every number anyone quotes about KPV comes from one of a small number of experimental systems, and the systems constrain what the numbers can mean far more tightly than the numbers themselves suggest. A reader who knows what Caco-2 is will read 'nanomolar anti-inflammatory activity' differently from one who does not. This is not scepticism about the work; the systems described here are standard, well-validated tools that were the correct choice for the questions asked. It is about matching the size of a claim to the system that produced it.

Caco-2 and HT29: intestinal epithelium, with caveats

Caco-2 is derived from a human colon adenocarcinoma. Grown to confluence and allowed to differentiate, it spontaneously develops many features of small-intestinal epithelium: polarised monolayers, tight junctions, brush-border enzymes and, relevantly here, peptide transporter expression. The BBE subclone used in this work was selected for brush-border expression. That makes it the standard model for intestinal absorption studies and a reasonable place to ask whether a transporter carries a substrate. It is also a cancer line, immortalised, grown without the microbiome, immune cells, mucus layer, blood supply or mechanical environment of a real intestine, and its transporter expression does not necessarily match a healthy person's. HT29-Cl.19A is a second colonic line used alongside it, which guards against a result being an artefact of one cell line. That is a useful control, because many studies do not bother.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

Jurkat: a leukaemic T-cell line

Jurkat cells are an immortalised human T-cell leukaemia line, used for decades because they are easy to grow and have well-characterised signalling. They are a legitimate tool for asking whether a compound affects a signalling pathway in a T cell. They are not primary human T cells, their signalling differs from primary cells in documented ways, and a result in Jurkat is a hypothesis about lymphocytes rather than a description of them.

What a luciferase reporter measures

An NF-kappaB luciferase reporter is a construct: a promoter containing NF-kappaB binding sites drives an enzyme whose activity is read as light. It is a fast, sensitive and quantitative way to ask whether a pathway's transcriptional output moved. It measures the construct, not the endogenous gene programme, and it can respond to things that affect the reporter without affecting the biology. This is why the 2008 KPV work is stronger than a reporter study alone. It added Western blot, real-time RT-PCR and ELISA, so the signal was followed from transcription factor activity through to secreted protein.

Why nanomolar in a dish is not a dose

A concentration in a culture well is set by the experimenter and held roughly constant. A concentration in an animal is the outcome of absorption, distribution, metabolism and excretion, varies continuously, and differs between tissues. Nanomolar activity says the molecule is potent against its target in that system; it says nothing about whether that concentration is reachable at the relevant tissue in a living organism, for how long, or at what cost elsewhere. Translating one into the other is the entire discipline of pharmacokinetics, and for KPV it has not been done in humans at all.

The mouse models, and the size of the remaining gap

Dextran sulfate sodium and trinitrobenzene sulfonic acid colitis are chemically induced injuries with different immunological characters (the first largely epithelial-barrier driven, the second more T-cell mediated), which is why using both, as the 2008 work did, is better than using one. Neither reproduces the cause or course of human inflammatory bowel disease. The AOM/DSS model used in the later knockout work induces tumours chemically on a background of chemical colitis. All three are tools for probing mechanism. The historical record of compounds that worked in rodent colitis models and then failed in people is long, and it is the main reason a result in these systems is a reason to keep looking rather than a conclusion.

Frequently asked questions

Is cell line work worthless then?

No. It is where mechanism gets established, and the KPV transport work is a good example of what it does well. The error is not doing the experiment; it is quoting its numbers as though they described a person.

Why use a cancer-derived line to model a healthy gut?

Because primary intestinal epithelial cells are difficult to obtain and do not survive long in culture. Caco-2 is the practical compromise the field settled on, and its limitations are well documented rather than hidden. Organoid systems now offer an alternative, and none of the KPV work described here used them.

What would it take to know whether KPV does anything in people?

A registered clinical trial with a defined population, a comparator, a pre-specified endpoint and an analysis plan. None exists. Until one does, everything on this subject is preclinical, and describing it otherwise would be false.

Does this apply to other compounds in this library?

To most of them, yes. Reading what system a number came from before reading the number itself is the single most useful habit for anyone working through a preclinical literature.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.